Roche signs deal to acquire Schroders’s Carmot Therapeutics for upto $3.1 billion
LONDON, UK: Schroders Capital’s portfolio company Carmot Therapeutics Inc. has entered into a definitive agreement to be acquired by Roche, a global pharmaceutical company, at a purchase price of $2.7 billion upfront and the potential for $400 million in milestone…